News Conference News HFSA 2022 REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status L.A. McKeown October 07, 2022
News Daily News Concerning or Reassuring? Long After COVID-19, CMR Still Yields Clues Michael O'Riordan October 03, 2022
News Conference News ESC Heart Failure 2022 Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE Todd Neale May 31, 2022
News Daily News The Hunt for Protein Culprits in COVID-19’s Cardiac Complications Michael O'Riordan May 06, 2022